Stage IV Pancreatic Cancer Clinical Trial
Official title:
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
This randomized phase I/II trial is studying gemcitabine hydrochloride and vismodegib to see how well they work compared with gemcitabine hydrochloride alone in treating patients with recurrent or metastatic pancreatic cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vismodegib may slow the growth of tumor cells. It is not yet known whether giving gemcitabine hydrochloride together with vismodegib is more effective than gemcitabine hydrochloride alone in treating patients with pancreatic cancer.
Status | Completed |
Enrollment | 118 |
Est. completion date | January 2013 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - Patients must have histologically or cytologically confirmed adenocarcinoma of the pancreas - Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan - Patients must have either: - Newly diagnosed chemo-naïve metastatic pancreatic cancer; only patients who have not received any chemotherapy for their metastatic disease are eligible - Recurrent disease after curative-intent surgery which has now recurred and is metastatic; patients who have recurrent disease may have received adjuvant chemotherapy or adjuvant chemoradiation, but may not have received any chemotherapy for metastatic disease; adjuvant therapy must have been completed >= 6 months prior to the diagnosis of recurrent disease, or if not adjuvant therapy received, surgery must have been performed >= 6 months prior to the diagnosis of recurrent disease - Age >= 21 years - Life expectancy > 3 months - Karnofsky performance status >= 80% - Granulocytes >= 1,500/mcL - Platelet count >= 100,000/mcL - Total bilirubin =< 1.5 times upper limit of normal (ULN) - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (ULN) (=< 5 times ULN in the presence of liver metastases) - Creatinine within normal institutional limit (< 1.5) OR creatinine clearance >= 65 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal - International normalized ratio (INR) =< 1.5 (=< 3 for patients on warfarin) - Patients who are on warfarin anticoagulation are allowed to participate as long as they fit the following 4 criteria: - They are therapeutic on a stable warfarin dose - Their INR target range is no greater than 3 - They are monitored with weekly INR testing - They have no active bleeding or pathological condition that carries high risk of bleeding Other anticoagulants, including enoxaparin (Lovenox) and fondaparinux (Arixtra) are also permitted - Women of child-bearing potential and men must use at least one form of contraception (i.e., barrier contraception) at least 4 weeks prior to study entry and then two forms of contraception (i.e barrier contraception and one other method of contraception), for the duration of study participation, and for at least 12 months post-treatment; for appropriate methods of contraception considered acceptable; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately - Pregnancy Testing: Women of childbearing potential are required to have a negative serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 10-14 days (at initial screening/consideration for the trial - serum or urine); a pregnancy test (serum or urine) will be administered every 4 weeks if their menstrual cycles are regular or every 2 weeks if their cycles are irregular while on study within the 24-hour period prior to the administration of GDC-0449; a positive urine test must be confirmed by a serum pregnancy test; prior to dispensing GDC-0449, the investigator must confirm and document the patient's use of two contraceptive methods, dates of negative pregnancy test, and confirm the patient's understanding of the teratogenic potential of GDC-0449 - Ability to understand and the willingness to sign a written informed consent document - Patients with recurrent disease after curative-intent surgical resection must have sufficient archival material for correlative studies (20 unstained 5 micron slides and 20 unstained 10 micron slides, or an archival tissue block Exclusion Criteria: - No prior chemotherapy for metastatic pancreatic cancer; patients who have received any chemotherapy and/or radiation therapy in the adjuvant setting must have completed this therapy =6 months prior to enrollment on the trial at the time of recurrence - Patients may not be receiving (or received prior to enrollment) any other investigational agents for metastatic disease - Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events - History of allergic reactions attributed to compounds of similar chemical or biologic composition to hedgehog antagonist GDC-0449 or any other agents used in this study - History of allergic reactions attributed to compounds of similar chemical or biologic composition to GDC-0449 or other agents used in the study - GDC-0449 inhibits CYP2C8, CYP2C9, and CYP2C19 drug metabolism enzymes in vitro at concentrations that may be clinically relevant. Therefore, caution should be exercised when dosing GDC-0449 concurrently with medications that are substrates of CYP2C8, CYP2C9, and CYP2C19 and have narrow therapeutic windows - Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption; patients must be able to swallow capsules - Patients with clinically active liver disease, including active viral or other hepatitis or cirrhosis are ineligible - Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, or hypokalemia, defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation are excluded from this study - No currently active second malignancy other than non-melanoma skin cancer or carcinoma in-situ of the cervix; patients are not considered to have a "currently active" malignancy if they have completed therapy and have no evidence of recurrence for at least 5 years - Uncontrolled intercurrent illness including, but not limited to, - Ongoing or active infection, - Symptomatic congestive heart failure - Unstable angina pectoris - Cardiac arrhythmia - Psychiatric illness or social situation that would limit compliance with study requirements - Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-0449; these potential risks may also apply to other agents used in this study - Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with GDC-0449; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
United States | University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland |
United States | Tower Cancer Research Foundation | Beverly Hills | California |
United States | Montefiore Medical Center | Bronx | New York |
United States | Montefiore Medical Center-Weiler Division | Bronx | New York |
United States | University of Chicago | Chicago | Illinois |
United States | Decatur Memorial Hospital | Decatur | Illinois |
United States | City of Hope Medical Center | Duarte | California |
United States | NorthShore University HealthSystem-Evanston Hospital | Evanston | Illinois |
United States | Fort Wayne Medical Oncology and Hematology Inc-Parkview | Fort Wayne | Indiana |
United States | Ingalls Memorial Hospital | Harvey | Illinois |
United States | Penn State Milton S Hershey Medical Center | Hershey | Pennsylvania |
United States | University of Southern California/Norris Cancer Center | Los Angeles | California |
United States | Loyola University Medical Center | Maywood | Illinois |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | New York University Clinical Cancer Center | New York | New York |
United States | New York University Langone Medical Center | New York | New York |
United States | Weill Medical College of Cornell University | New York | New York |
United States | City of Hope Medical Group Inc | Pasadena | California |
United States | Illinois CancerCare-Peoria | Peoria | Illinois |
United States | University of Pittsburgh | Pittsburgh | Pennsylvania |
United States | University of California at Davis Cancer Center | Sacramento | California |
United States | Saint John's Mercy Medical Center | Saint Louis | Missouri |
United States | Central Illinois Hematology Oncology Center | Springfield | Illinois |
United States | Southern Illinois University | Springfield | Illinois |
United States | University of Maryland Saint Joseph Medical Center | Towson | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free Survival | Time from randomization to disease progression or death from any cause. Estimated in the two treatment groups by the Kaplan-Meier method and compared using a stratified logrank test. | Up to 3 years | No |
Secondary | Overall Survival | Time from randomization to death from any cause. Estimated in the two treatment groups by the Kaplan-Meier method and compared using a stratified logrank test. | Up to 3 years | No |
Secondary | Objective Response Rate | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. | Up to 6 months | No |
Secondary | Incidence of Adverse Events | Details are provided in Adverse Events section below. Reported here are percentage of patients in each arm with any grade 1 or higher adverse event, regardless of attribution. | Up to 3 years | Yes |
Secondary | Activity (Overall Response Rate) in Crossover Patients | RECIST response rate in patients after crossover from placebo to vismodegib arm. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. | Up to 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT02005315 -
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT01453153 -
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00095966 -
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02178436 -
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01647828 -
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01555489 -
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
|
Phase 2 | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT01232829 -
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
|
Phase 2 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00735917 -
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02896907 -
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT02307539 -
Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer
|
N/A | |
Completed |
NCT02050178 -
Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT01488552 -
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01222689 -
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00397787 -
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT01893801 -
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
|
Phase 1/Phase 2 |